Jayastu Senapati, MBBS

MD Anderson Cancer Center

Latest Content

Azacitidine and venetoclax combination therapy for AML, showcasing practice-changing insights from ASH 2025 presented by Jayastu Senapati and Uma Borate.

Leukemia

01/16/2026

Azacitidine in AML: Key Takeaways From the PARADIGM Study

Jayastu Senapati, MBBSUma Borate, MBBS

1. Expert oncologists discussing treatment options for cancer, emphasizing Venetoclax-based regimens, targeted agents, and rapid molecular profiling for personalized therapy.

Leukemia

12/23/2025

Improving Venetoclax and Other Targeted Therapies in AML

Zachary Braunstein, MDJayastu Senapati, MBBS